GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medlab Clinical Ltd (ASX:MDC) » Definitions » ROA %

Medlab Clinical (ASX:MDC) ROA % : -225.05% (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Medlab Clinical ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Medlab Clinical's annualized Net Income for the quarter that ended in Dec. 2023 was A$-3.96 Mil. Medlab Clinical's average Total Assets over the quarter that ended in Dec. 2023 was A$1.76 Mil. Therefore, Medlab Clinical's annualized ROA % for the quarter that ended in Dec. 2023 was -225.05%.

The historical rank and industry rank for Medlab Clinical's ROA % or its related term are showing as below:

ASX:MDC' s ROA % Range Over the Past 10 Years
Min: -118.21   Med: -67.33   Max: -31.49
Current: -118.21

During the past 8 years, Medlab Clinical's highest ROA % was -31.49%. The lowest was -118.21%. And the median was -67.33%.

ASX:MDC's ROA % is not ranked
in the Biotechnology industry.
Industry Median: -35.26 vs ASX:MDC: -118.21

Medlab Clinical ROA % Historical Data

The historical data trend for Medlab Clinical's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medlab Clinical ROA % Chart

Medlab Clinical Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
ROA %
Get a 7-Day Free Trial -36.34 -70.53 -64.13 -44.74 -93.42

Medlab Clinical Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -33.25 -59.79 -107.90 -81.50 -225.05

Competitive Comparison of Medlab Clinical's ROA %

For the Biotechnology subindustry, Medlab Clinical's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medlab Clinical's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medlab Clinical's ROA % distribution charts can be found below:

* The bar in red indicates where Medlab Clinical's ROA % falls into.



Medlab Clinical ROA % Calculation

Medlab Clinical's annualized ROA % for the fiscal year that ended in Jun. 2023 is calculated as:

ROA %=Net Income (A: Jun. 2023 )/( (Total Assets (A: Jun. 2022 )+Total Assets (A: Jun. 2023 ))/ count )
=-6.778/( (11.367+3.144)/ 2 )
=-6.778/7.2555
=-93.42 %

Medlab Clinical's annualized ROA % for the quarter that ended in Dec. 2023 is calculated as:

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=-3.962/( (3.144+0.377)/ 2 )
=-3.962/1.7605
=-225.05 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Dec. 2023) net income data. ROA % is displayed in the 30-year financial page.


Medlab Clinical  (ASX:MDC) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-3.962/1.7605
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-3.962 / 0.096)*(0.096 / 1.7605)
=Net Margin %*Asset Turnover
=-4127.08 %*0.0545
=-225.05 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2023) net income data. The Revenue data used here is two times the semi-annual (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Medlab Clinical ROA % Related Terms

Thank you for viewing the detailed overview of Medlab Clinical's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Medlab Clinical (ASX:MDC) Business Description

Traded in Other Exchanges
N/A
Address
11 Lord Street, Unit 5, Botany, NSW, AUS, 2019
Medlab Clinical Ltd is a medical research and development company. It is engaged in researching and formulating novel biotherapeutics to improve health outcomes in early to moderate stage chronic diseases such as chronic kidney disease, pre-diabetes, and obesity. Some of the company's nutraceutical products are Multibiotic, Mg Optima Relax, NRGBiotic, NanoCelle D3, SB 5B and others. The principal segments of the group are Nutraceutical which includes the sale of nutraceutical products; and Pharmaceutical research. It generates the majority of the revenue from the sale of nutraceutical products. The business operations of the firm are carried out from Australia.